There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Immuneering (IMRX – Research Report), PepGen Inc. (PEPG – Research Report) and Relmada Therapeutics (RLMD – Research Report) with bullish sentiments.
Immuneering (IMRX)
In a report issued on October 12, Mara Goldstein from Mizuho Securities maintained a Buy rating on Immuneering, with a price target of $20.00. The company’s shares closed last Monday at $6.02.
According to TipRanks.com, Goldstein has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Currently, the analyst consensus on Immuneering is a Strong Buy with an average price target of $20.25.
See Insiders’ Hot Stocks on TipRanks >>
PepGen Inc. (PEPG)
Leerink Partners analyst Joseph Schwartz maintained a Buy rating on PepGen Inc. on October 12. The company’s shares closed last Monday at $5.42, close to its 52-week low of $4.26.
According to TipRanks.com, Schwartz is ranked 0 out of 5 stars with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for PepGen Inc. with a $24.00 average price target, representing a 317.4% upside. In a report issued on October 12, H.C. Wainwright also maintained a Buy rating on the stock with a $26.00 price target.
Relmada Therapeutics (RLMD)
Mizuho Securities analyst Uy Ear maintained a Buy rating on Relmada Therapeutics on October 12 and set a price target of $25.00. The company’s shares closed last Monday at $3.13.
According to TipRanks.com, Ear is a 4-star analyst with an average return of
Relmada Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $25.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on IMRX:
